RGBiotech Logo  
Find Products & Services By Categories.
Search




Home -> Support -> Articles -> Brief Introduction of Recombinant AAV
 
Quick Inquiry  

Brief Introduction of Recombinant AAV

Wild type adeno associated viruses (wtAAVs) are small, non-enveloped viruses with a 4.7kb single-stranded DNA genome. Scientists have developed recombinant AAVs (rAAVs) as efficient transfer vectors that have been successfully utilized in many in vitro and in vivo applications.

There is a set of unique characteristics which make rAAVs attractive as a genetic delivery vector. 1) Unlike human pathogenic HIV-derived recombinant lentiviruses (rLVs), wtAAVs are have not been reported to be associated with any human diseases. The engineered rAAVs are safer for researchers or end users. 2) Although wtAAVs can integrate into human chromosome 19 at the locus known as AAVS1 (or PPP1R12C), rAAVs has been eliminated the integrative ability by removal of the rep and cap from the recombinant viral genome, which means rAAVs can not cause insertional mutagenesis resulting from the integration. 3) Like rLVs, rAAVs can infect both dividing and non-dividing cells. 4) rAAVs have several serotypes targeting different specific cell types or tissues.

There are multiple methods to produce rAAVs, but typical strategies include helper-free AAV production system and baculovirus-based AAV production system. The helper-free system involves transfecting packaging cells with three different plasmids, 1) vector containing ITR-flanked GOI, 2) vector containing the replication (rep) and capsid (cap) genes, and 3) vector containing essential helper virus genes such as adenovirus E4, E2A and VA. The baculovirus-based AAV production system briefly involves two steps, 1) generation of GOI and helper baculoviruses, 2) co-infection of two baculoviruses into insect cells to achieve rAAVs. The baculovirus-based system is typically used for large scale AAV manufacturing.

rAAVs can be divided into different subgroups according to the viral genome and their cap proteins.

1) Numerous AAV serotypes have been identified, but the best characterized is AAV2. So far, almost all rAAVs have utilized ITRs from AAV serotype 2.

2) AAV variants: Single-stranded AAV (ssAAV) & Self-complementary AAV (scAAV)
ssAAV is the traditional rAAVs vetors. The genome of ssAAV is a linear single-stranded (ss) DNA molecule with a length of approximately 4.7 kb. scAAV is a derivative of ssAAV and its genome is an intra-molecular double-stranded DNA. Compared with ssAAV, scAAV has faster and higher levels of gene expression as it circumvents the step of second second-strand synthesis. The disadvantage of scAAV is its smaller cargo capacity which is ~2.2 kb.

3) AAV serotypes
Serotype is determined by the type of capsid protein. So far, rAAVs have been equipped with several capsid proteins and have been successfully used in many in vitro / in vivo experiments. These serotypes include AAV1, 2, 3, 4, 5, 6, 7, 8, 9, DJ, DJ-8, PHP.B, PHP.eB, PHP.S, rh10, Retrograde, B1, 7m8, shh10, Anc80L65AAP, Anc80L65, with more under development.

Related Products: AAV Production Plasmids
Item No. Description Price
PKIT-211221 Plasmids for producing recombinant AAV2 / 1 Inquiry
PKIT-211222 Plasmids for producing recombinant AAV2 / 2 Inquiry
PKIT-211223 Plasmids for producing recombinant AAV2 / 3 Inquiry
PKIT-211224 Plasmids for producing recombinant AAV2 / 4 Inquiry
PKIT-211225 Plasmids for producing recombinant AAV2 / 5 Inquiry
PKIT-211226 Plasmids for producing recombinant AAV2 / 6 Inquiry
PKIT-211227 Plasmids for producing recombinant AAV2 / 7 Inquiry
PKIT-211228 Plasmids for producing recombinant AAV2 / 8 Inquiry
PKIT-211229 Plasmids for producing recombinant AAV2 / 9 Inquiry
PKIT-2112210 Plasmids for producing recombinant AAV2 / DJ Inquiry
PKIT-2112211 Plasmids for producing recombinant AAV2 / DJ-8 Inquiry
PKIT-2112212 Plasmids for producing recombinant AAV2 / PHP.B Inquiry
PKIT-2112213 Plasmids for producing recombinant AAV2 / PHP.eB Inquiry
PKIT-2112214 Plasmids for producing recombinant AAV2 / PHP.S Inquiry
PKIT-2112215 Plasmids for producing recombinant AAV2 / rh10 Inquiry
PKIT-2112216 Plasmids for producing recombinant AAV2 / Retrograde Inquiry
PKIT-2112217 Plasmids for producing recombinant AAV2 / B1 Inquiry
PKIT-2112218 Plasmids for producing recombinant AAV2 / 7m8 Inquiry
PKIT-2112219 Plasmids for producing recombinant AAV2 / shh10 Inquiry
PKIT-2112220 Plasmids for producing recombinant AAV2 / Anc80L65AAP Inquiry
PKIT-2112221 Plasmids for producing recombinant AAV2 / Anc80L65 Inquiry
PKIT-243241 Plasmids for producing recombinant AAV2 / Myo2A Inquiry
PKIT-243242 Plasmids for producing recombinant AAV2 / Spark100 Inquiry
PKIT-243243 Plasmids for producing recombinant AAV2 / LK03 (Spark200) Inquiry

For More Readings

[1] Douglas M McCarty. Self-complementary AAV vectors; advances and applications. Mol Ther. 2008 Oct;16(10):1648-56. doi: 10.1038/mt.2008.171. PMID: 18682697 DOI: 10.1038/mt.2008.171.
[2] Deepak Raj, Andrew M Davidoff, and Amit C Nathwani. Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges. Expert Rev Hematol. 2011 Oct; 4(5): 539–549. doi: 10.1586/ehm.11.48. PMCID: PMC3200187. PMID: 21939421.
[3] Anne K Zaiss, Daniel A Muruve. Immune responses to adeno-associated virus vectors. Curr Gene Ther. 2005 Jun;5(3):323-31. doi: 10.2174/1566523054065039. PMID: 15975009 DOI: 10.2174/1566523054065039
[4] Zhijian Wu, Aravind Asokan, R Jude Samulski. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther. 2006 Sep;14(3):316-27. doi: 10.1016/j.ymthe.2006.05.009. Epub 2006 Jul 7. PMID: 16824801 DOI: 10.1016/j.ymthe.2006.05.009.
[5] Michael F. Naso,corresponding author Brian Tomkowicz, William L. Perry, III, and William R. Strohl. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. 2017; 31(4): 317–334. PMCID: PMC5548848. PMID: 28669112

 

Products & Services
Resources
     
 
  Home
Products & Services
Support
About Us
Contact Us
Promotions
Flyers
Brochures
Publications
News & Events
Terms & Conditions
Privacy
Disclaimers

Contact Us

EMAIL: admin@rgbiotech.com
 
 
© RGBiotech All Rights Reserved.